Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1972 Dec;2(6):423–426. doi: 10.1128/aac.2.6.423

Clotrimazole (Bay b 5097): In Vitro and Clinical Pharmacological Studies

M A Burgess 1, Gerald P Bodey 1
PMCID: PMC444333  PMID: 4677595

Abstract

Clotrimazole (Bay b 5097) is a new synthetic antifungal drug with in vitro activity against Candida spp., Torulopsis glabrata, and Saccharomyces spp. Pharmacological studies in man after the oral administration of 1.5 and 3 g of clotrimazole produced mean peak concentrations in the serum of 1.16 and 1.29 μg/ml, respectively, 2 hr after administration. In six patients taking 1.5 g of clotrimazole every 6 hr, there was a progressive decline in the serum concentrations after administration of a dose on days 1, 4, and 8. Nine other patients begun on a similar schedule manifested gastrointestinal symptoms attributed to the clotrimazole and were unable to complete the study. Concentrations of active drug in the urine were less than 1% of the administered dose.

Full text

PDF
426

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P. Fungal infections complicating acute leukemia. J Chronic Dis. 1966 Jun;19(6):667–687. doi: 10.1016/0021-9681(66)90066-x. [DOI] [PubMed] [Google Scholar]
  2. Bodey G. P. Oral antibiotic prophylaxis in protected environment units: effect of nonabsorbable and absorbable antibiotics on the fecal flora. Antimicrob Agents Chemother. 1972 Apr;1(4):343–347. doi: 10.1128/aac.1.4.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Evans E. G., Watson D. A., Matthews N. R. Pulmonary aspergillomata in a child treated with clotrimazole. Br Med J. 1971 Dec 4;4(5787):599–600. doi: 10.1136/bmj.4.5787.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Goldstein E., Hoeprich P. D. Problems in the diagnosis and treatment of systemic candidiasis. J Infect Dis. 1972 Feb;125(2):190–193. doi: 10.1093/infdis/125.2.190. [DOI] [PubMed] [Google Scholar]
  5. HILL G. J., 2nd AMPHOTERICIN B TOXICITY; CHANGES IN RENAL MORPHOLOGY. Ann Intern Med. 1964 Aug;61:349–354. [PubMed] [Google Scholar]
  6. Hughes W. T. Fatal infections in childhood leukemia. Am J Dis Child. 1971 Oct;122(4):283–287. doi: 10.1001/archpedi.1971.02110040067003. [DOI] [PubMed] [Google Scholar]
  7. Marget W., Adam D. Bay B 5097, a new orally applicable antifungal substance with broadspectrum activity. Preliminary clinical and laboratory experiences in children. Acta Paediatr Scand. 1971 May;60(3):341–345. doi: 10.1111/j.1651-2227.1971.tb06668.x. [DOI] [PubMed] [Google Scholar]
  8. Marks M. I., Steer P., Eickhoff T. C. In vitro sensitivity of Torulopsis glabrata to amphotericin B, 5-fluorocytosine, and clotrimazole (Bay 5097). Appl Microbiol. 1971 Jul;22(1):93–95. doi: 10.1128/am.22.1.93-95.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Oberste-Lehn H., Baggesen I., Plempel M. Erste klinische Erfahrungen bei System-Mykosen mit einem neuen oralen Antimykotikum. Dtsch Med Wochenschr. 1969 Jun 27;94(26):1365–passim. doi: 10.1055/s-0028-1111224. [DOI] [PubMed] [Google Scholar]
  10. Plempel M., Bartmann K., Büchel K. H., Regel E. BAY b 5097, a new orally applicable antifungal substance with broad-spectrum activity. Antimicrob Agents Chemother (Bethesda) 1969;9:271–274. [PubMed] [Google Scholar]
  11. Rifkind D., Marchioro T. L., Schneck S. A., Hill R. B., Jr Systemic fungal infections complicating renal transplantation and immunosuppressive therapy. Clinical, microbiologic, neurologic and pathologic features. Am J Med. 1967 Jul;43(1):28–38. doi: 10.1016/0002-9343(67)90146-5. [DOI] [PubMed] [Google Scholar]
  12. Rose H. D., Heckman M. G. Persistent fungemia caused by Torulopsis glabrata: treatment with amphotericin B. Am J Clin Pathol. 1970 Aug;54(2):205–208. doi: 10.1093/ajcp/54.2.205. [DOI] [PubMed] [Google Scholar]
  13. Shadomy S. In vivo studies with Bay b 5097. Antimicrob Agents Chemother (Bethesda) 1970;10:169–174. [PubMed] [Google Scholar]
  14. Solberg C. O., Meuwissen H. J., Needham R. N., Good R. A., Matsen J. M. Infectious complications in bone marrow transplant patients. Br Med J. 1971 Jan 2;1(5739):18–23. doi: 10.1136/bmj.1.5739.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Steer P. L., Marks M. I., Klite P. D., Eickhoff T. C. 5-fluorocytosine: an oral antifungal compound. A report on clinical and laboratory experience. Ann Intern Med. 1972 Jan;76(1):15–22. doi: 10.7326/0003-4819-76-1-15. [DOI] [PubMed] [Google Scholar]
  16. Stein P. D., Folkens A. T., Hruska K. A. Saccharomyces fungemia. Chest. 1970 Aug;58(2):173–175. doi: 10.1378/chest.58.2.173. [DOI] [PubMed] [Google Scholar]
  17. Stinson E. B., Bieber C. P., Griepp R. B., Clark D. A., Shumway N. E., Remington J. S. Infectious complications after cardiac transplantation in man. Ann Intern Med. 1971 Jan;74(1):22–36. doi: 10.7326/0003-4819-74-1-22. [DOI] [PubMed] [Google Scholar]
  18. Vandevelde A. G., Mauceri A. A., Johnson J. E., 3rd 5-fluorocytosine in the treatment of mycotic infections. Ann Intern Med. 1972 Jul;77(1):43–51. doi: 10.7326/0003-4819-77-1-43. [DOI] [PubMed] [Google Scholar]
  19. Waitz J. A., Moss E. L., Weinstein M. J. Chemotherapeutic evaluation of clotrimazole (Bay b 5097, 1 (o-chloro- - -diphenylbenzyl) imidazole). Appl Microbiol. 1971 Nov;22(5):891–898. doi: 10.1128/am.22.5.891-898.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES